50 related articles for article (PubMed ID: 12467225)
1. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.
Epel M; Carmi I; Soueid-Baumgarten S; Oh S; Bera T; Pastan I; Berzofsky J; Reiter Y
Eur J Immunol; 2008 Jun; 38(6):1706-20. PubMed ID: 18446790
[TBL] [Abstract][Full Text] [Related]
2. Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta.
Nagai T; Tanaka M; Tsuneyoshi Y; Xu B; Michie SA; Hasui K; Hirano H; Arita K; Matsuyama T
Cancer Immunol Immunother; 2009 Oct; 58(10):1577-86. PubMed ID: 19238383
[TBL] [Abstract][Full Text] [Related]
3. A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer.
Zimmermann S; Wels W; Froesch BA; Gerstmayer B; Stahel RA; Zangemeister-Wittke U
Cancer Immunol Immunother; 1997 Mar; 44(1):1-9. PubMed ID: 9111578
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.
Liu XF; Xiang L; FitzGerald DJ; Pastan I
Mol Cancer Ther; 2014 Jan; 13(1):82-9. PubMed ID: 24145282
[TBL] [Abstract][Full Text] [Related]
5. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.
Tsutsumi Y; Onda M; Nagata S; Lee B; Kreitman RJ; Pastan I
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8548-53. PubMed ID: 10890891
[TBL] [Abstract][Full Text] [Related]
6. A divalent recombinant immunotoxin formed by a disulfide bond between the extension peptide chains.
Park JH; Kwon HW; Chung HK; Kim IH; Ahn K; Choi EJ; Pastan I; Choe M
Mol Cells; 2001 Dec; 12(3):398-402. PubMed ID: 11804341
[TBL] [Abstract][Full Text] [Related]
7. Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.
Wei H; Xiang L; Wayne AS; Chertov O; FitzGerald DJ; Bera TK; Pastan I
Proc Natl Acad Sci U S A; 2012 May; 109(18):6898-903. PubMed ID: 22509046
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Hassan R; Ebel W; Routhier EL; Patel R; Kline JB; Zhang J; Chao Q; Jacob S; Turchin H; Gibbs L; Phillips MD; Mudali S; Iacobuzio-Donahue C; Jaffee EM; Moreno M; Pastan I; Sass PM; Nicolaides NC; Grasso L
Cancer Immun; 2007 Dec; 7():20. PubMed ID: 18088084
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome.
Wang H; Song S; Kou G; Li B; Zhang D; Hou S; Qian W; Dai J; Tian L; Zhao J; Guo Y
Cancer Immunol Immunother; 2007 Nov; 56(11):1775-83. PubMed ID: 17431617
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.
Yuan X; Yang M; Chen X; Zhang X; Sukhadia S; Musolino N; Bao H; Chen T; Xu C; Wang Q; Santoro S; Ricklin D; Hu J; Lin R; Yang W; Li Z; Qin W; Zhao A
Cancer Immunol Immunother; 2017 Mar; 66(3):367-378. PubMed ID: 27933426
[TBL] [Abstract][Full Text] [Related]
11. Production of a Granulysin-Based, Tn-Targeted Cytolytic Immunotoxin Using Pulsed Electric Field Technology.
Guerrero-Ochoa P; Aguilar-Machado D; Ibáñez-Pérez R; Macías-León J; Hurtado-Guerrero R; Raso J; Anel A
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32859066
[TBL] [Abstract][Full Text] [Related]
12.
Havaei SM; Aucoin MG; Jahanian-Najafabadi A
Front Oncol; 2021; 11():781800. PubMed ID: 34976821
[TBL] [Abstract][Full Text] [Related]
13. Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity.
Wei J; Bera TK; Liu XF; Zhou Q; Onda M; Ho M; Tai CH; Pastan I
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3501-E3508. PubMed ID: 29581296
[TBL] [Abstract][Full Text] [Related]
14. Production of unique immunotoxin cancer therapeutics in algal chloroplasts.
Tran M; Van C; Barrera DJ; Pettersson PL; Peinado CD; Bui J; Mayfield SP
Proc Natl Acad Sci U S A; 2013 Jan; 110(1):E15-22. PubMed ID: 23236148
[TBL] [Abstract][Full Text] [Related]
15. A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.
Gattenlöhner S; Jörissen H; Huhn M; Vincent A; Beeson D; Tzartos S; Mamalaki A; Etschmann B; Muller-Hermelink HK; Koscielniak E; Barth S; Marx A
J Biomed Biotechnol; 2010; 2010():187621. PubMed ID: 20204062
[TBL] [Abstract][Full Text] [Related]
16. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.
Zhang Y; Xiang L; Hassan R; Pastan I
Proc Natl Acad Sci U S A; 2007 Oct; 104(43):17099-104. PubMed ID: 17940013
[TBL] [Abstract][Full Text] [Related]
17. Immunotoxins for targeted cancer therapy.
Kreitman RJ
AAPS J; 2006 Aug; 8(3):E532-51. PubMed ID: 17025272
[TBL] [Abstract][Full Text] [Related]
18. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer.
Bera TK; Williams-Gould J; Beers R; Chowdhury P; Pastan I
Mol Cancer Ther; 2001 Dec; 1(2):79-84. PubMed ID: 12467225
[TBL] [Abstract][Full Text] [Related]
19. A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2.
Bera TK; Onda M; Brinkmann U; Pastan I
J Mol Biol; 1998 Aug; 281(3):475-83. PubMed ID: 9698563
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
